Innocoll Starts Phase II Trial for Diabetic Foot Ulcer Treatment
Posted on: Wednesday, 19 December 2007, 09:01 CST
Innocoll has reported that dosing has commenced for the first of three planned Phase II clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies, to investigate CollaRx gentamicin topical for the treatment and prevention of infected diabetic foot ulcers.
Innocoll plans to study CollaRx gentamicin topical for the treatment of diabetic foot infections of varying severity in a series of Phase II trials and has appointed the full-service clinical research organization, Premier Research Group, to coordinate the trials and provide US regulatory support.
The first of these trials is for the treatment of mildly infected diabetic ulcers, where the safety and efficacy of CollaRx gentamicin topical will be compared to an orally administered antibiotic.
This is a multi-centered trial performed at 10 sites, nine in the US and one in the UK. In two subsequent controlled, multi-centered Phase II trials due to commence in early 2008, Innocoll will investigate the product as an adjunct to systemic therapy for treating moderately infected ulcers and also as a therapy to prevent ulcers from becoming clinically infected.
Source: Datamonitor
Related Articles
- Innocoll Announces Provisional Findings From Its Three Phase 2 Clinical Trials Investigating CollaRx(R) GENTAMICIN TOPICAL for the Treatment and Prevention of Diabetic Foot Infections
- Living Cell Technologies Receives Health Minister's Approval to Start Leading Edge Live Cell Therapy Clinical Trial in New Zealand for Diabetics
- Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
- Oculus Innovative Sciences Completes Patient Treatment and Follow-Up in Its Phase II Clinical Trial in Mildly Infected Diabetic Foot Ulcers
- Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
- Chimerix Starts Multi-Dose Trial for Smallpox Infection
- Chimerix Initiates a Multi-Dose Clinical Trial of the Company's Lead Compound, CMX001, for the Treatment for Smallpox Infection
- Innocoll Files Investigational New Drug Application for Its CollaRx(R) BUPIVACAINE TOPICAL for the Treatment of Painful Chronic Skin Ulcers and Burns
- Innocoll Receives FDA Approval to Commence a Phase 2 Clinical Trial for the Topical Treatment of Infected Diabetic Foot Ulcers With Its CollaRx(R) GENTAMICIN
- Sangamo BioSciences Initiates Phase 2 Clinical Trial of Novel Therapy for Diabetic Neuropathy
 |
 |
User Comments (0)
RSS Feeds